Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Sep 7;56(9):453.
doi: 10.3390/medicina56090453.

Medicinal Cannabis and Synthetic Cannabinoid Use

Simona Pichini  1 , Alfredo Fabrizio Lo Faro  2 , Francesco Paolo Busardò  1 , Raffaele Giorgetti  1
Affiliations
Editorial

Medicinal Cannabis and Synthetic Cannabinoid Use

Simona Pichini et al. Medicina (Kaunas). .

Abstract

Cannabis products have been used for centuries by humans for recreational and medical purposes. Resent research, proposed the promising therapeutic potential of cannabis and related cannabinoids for a wide range of medical conditions, including psychiatric and neurological diseases. This Special Issue presents the latest updates on medicinal cannabis and synthetic cannabinoids pharmacology, toxicology and new analytical methods to identify and quantify these compounds in conventional and non-conventional biological matrices. Moreover, it provides current data regarding their adverse effects, safety, application for medical purposes and their harmful effects.

Keywords: gas chromatography-mass spectrometry; high-resolution mass spectrometry; liquid chromatography; synthetic cannabinoids; urine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. World Drug Report 2020. [(accessed on 29 July 2020)]; Available online: https://wdr.unodc.org/wdr2020/index.html.
    1. Mannucci C., Navarra M., Calapai F., Spagnolo E.V., Busardò F.P., Cas R.D., Ippolito F.M., Calapai G. Neurological aspects of medical use of cannabidiol. CNS Neurol. Disord. Drug Targets. 2017;16:541–553. doi: 10.2174/1871527316666170413114210. - DOI - PubMed
    1. Huestis M.A., Solimini R., Pichini S., Pacifici R., Carlier J., Busardò F.P. Cannabidiol Adverse Effects and Toxicity. Curr. Neuropharmacol. 2019;17:974–989. doi: 10.2174/1570159X17666190603171901. - DOI - PMC - PubMed
    1. Pacifici R., Pichini S., Pellegrini M., Tittarelli R., Pantano F., Mannocchi G., Rotolo M.C., Busardò F.P. Determination of cannabinoids in oral fluid and urine of “light cannabis” consumers: A pilot study. Clin. Chem. Lab. Med. 2018;57:238–243. doi: 10.1515/cclm-2018-0566. - DOI - PubMed
    1. Mammana S., Cavalli E., Gugliandolo A., Silvestro S., Pollastro F., Bramanti P., Mazzon E. Could the combination of two non-psychotropic cannabinoids counteract neuroinflammation? Effectiveness of cannabidiol associated with cannabigerol. Medicina. 2019;55:747. doi: 10.3390/medicina55110747. - DOI - PMC - PubMed

Publication types